Risk of respiratory, thoracic, and mediastinal disorders associated with endothelin receptor antagonists and prostacyclin-related drugs in pulmonary hypertension: a disproportionality analysis based on FAERS
The analysis highlights the RTMD risks of ERAs and PRDs in treating PH and underscores the need for careful monitoring of ADEs to ensure their safe and effective use in clinical practice.
Authors
- Xiaojuan Yang (ORCID: https://orcid.org/0000-0003-1323-9478)
- Q F
- Fengjie Tang (ORCID: https://orcid.org/0009-0005-4037-1193)
- Ying‐Hong Liu (ORCID: https://orcid.org/0009-0008-9145-6033)
Institutions
- Chongqing University (CN)
- Chongqing Emergency Medical Center (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2024-12-03
- DOI
- https://doi.org/10.1080/14740338.2024.2436077
- Citations
- 2
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.84